AML
Showing NaN - NaN of 22
Hematologic Malignancy, AML, ALL Trial in Australia, United States (Tagraxofusp, Fludarabine, Cytarabine)
Not yet recruiting
- Hematologic Malignancy
- +10 more
- Tagraxofusp
- +8 more
-
Los Angeles, California
- +28 more
Jul 26, 2022
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Canada, United States (CFI-400945, Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +5 more
- CFI-400945
- +2 more
-
Duarte, California
- +7 more
Jul 20, 2022
AML Trial in Worldwide (Flotetuzumab dose escalation, Flotetuzumab dose expansion, Ruxolitinib)
Active, not recruiting
- AML
- Flotetuzumab dose escalation
- +2 more
-
Duarte, California
- +42 more
Mar 7, 2022
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute Trial in Canada, United States (Iomab-B, Conventional
Active, not recruiting
- Acute Myeloid Leukemia
- +8 more
- Iomab-B
- +2 more
-
Gilbert, Arizona
- +23 more
Feb 22, 2022
AML, MDS Trial in United States (APVO436)
Recruiting
- AML
- MDS
- APVO436
-
San Francisco, California
- +11 more
Feb 8, 2022
Leukemia, AML, MDS Trial in Houston (Azacitidine)
Completed
- Leukemia
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 6, 2020
AML, Acute Myeloid Leukemia, Myelodysplastic Disorders Trial in Houston (Idarubicin, Sorafenib, Ara-C)
Completed
- AML
- +2 more
- Idarubicin
- +2 more
-
Houston, TexasThe University of Texas M.D. Anderson Cancer Center
Jul 23, 2018
Leukemia, Acute Myeloid Leukemia, AML Trial in Houston (Cytarabine, Idarubicin)
Completed
- Leukemia
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jul 23, 2018
AML, ALL, Blast Crisis Trial in United States (TG02 citrate, Carfilzomib, Dexamethasone)
Completed
- AML
- +4 more
- TG02 citrate
- +2 more
-
Denver, Colorado
- +8 more
May 5, 2016
Leukemia, AML, MDS Trial in Houston (Cytarabine, Fludarabine)
Completed
- Leukemia
- +3 more
-
Houston, TexasUT MD Anderson Cancer Center
Feb 17, 2016